AzerbaijanTuberculosis profile
Population  2016 9.7 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.62 (0.61–0.63) 6.4 (6.3–6.5)
Mortality (HIV+TB only) 0.028 (0.02–0.036) 0.28 (0.2–0.37)
Incidence  (includes HIV+TB) 6.4 (4.9–8.2) 66 (51–84)
Incidence (HIV+TB only) 0.13 (0.083–0.18) 1.3 (0.86–1.9)
Incidence (MDR/RR-TB)** 2.4 (2–2.9) 25 (20–30)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.35 (0.27–0.44) 1.8 (1.4–2.3) 2.2 (1.6–2.7)
Males 0.4 (0.3–0.5) 3.9 (2.9–4.9) 4.3 (3.2–5.4)
Total 0.76 (0.57–0.94) 5.7 (4.3–7.1) 6.4 (4.9–8.2)
TB case notifications, 2016  
Total cases notified 6 707
Total new and relapse 5 159
          - % tested with rapid diagnostics at time of diagnosis 39%
          - % with known HIV status 70%
          - % pulmonary 80%
          - % bacteriologically confirmed among pulmonary 61%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.1 (0.08–0.13)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 99 2%
          - on antiretroviral therapy 78 79%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 500
(1 400–1 600)
Estimated % of TB cases with MDR/RR-TB 13% (10–16) 39% (37–42)  
% notified tested for rifampicin resistance 31% 61% 2 955
MDR/RR-TB cases tested for resistance to second-line drugs   589
Laboratory-confirmed cases MDR/RR-TB: 925, XDR-TB: 77
Patients started on treatment **** MDR/RR-TB: 798, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New cases registered in 2015 83% 1 475
Previously treated cases registered in 2015 73% 2 738
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014 59% 745
XDR-TB cases started on second-line treatment in 2014 23% 69
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 60%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
86% (63–100)
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-20 Data: www.who.int/tb/data